Postelicitation model of allergic contact dermatitis for predicting the efficacy of topical drugs

Experimental Dermatology

Volumn 18, Issue 1, 2009, Pages 44-49

  Kammeyer, Arthur ^a   Bos, Jan D ^a   Teunissen, Marcel B M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Allergic contact dermatitis; Contact hypersensitivity murine model; Urocanic acid

Indexed keywords

4 IMIDAZOLEACETIC ACID; ANTIINFLAMMATORY AGENT; HYDROCORTISONE; IMIDAZOLE 4 CARBOXYLIC ACID; PLACEBO; PREDNISOLONE; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CONTACT ALLERGY; CONTACT DERMATITIS; CONTACT SENSITIZATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARBOXYLIC ACIDS; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, CONTACT; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; IMIDAZOLES; INFLAMMATION; MICE; MICE, INBRED BALB C;

EID: 57649232759     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00757.x     Document Type: Article

References (22)

1. Harada D, Takada C, Tsukomo Y, Takaba K, Manabe H. Analyses of a mouse model of the dermatitis caused by TNCB-repeated application. J Dermatol Sci 2005: 37: 159-167.
2. Lee S J, Oh S G, Seo S W et al. Oral administration of Astragalus membranaceus inhibits the development of DNFB-induced dermatitis in NC/ Nga mice. Biol Pharm Bull 2007: 30: 1468-1471.
3. Yamamoto S, Sugahara S, Ikeda K, Shimizu Y. Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models. Eur J Pharmacol 2006: 550: 166-172.
4. Bäumer W, Krekeler S, DeVries V C, Niedorf F, Tschernig T, Kietzmann M. Non-steroidal and steroidal anti-inflammatory drugs vary in their modulation of dendritic cell function in the elicitation phase of allergic contact dermatitis. Exp Dermatol 2006: 15: 322-329.
5. Lauerma A I, Homey B, Vohr H W, Lee C H, Bloom E, Maibach H I. Effect of topical cis-urocanic acid on lymph node activation during contact sensitization in mouse, rat and guinea pig. Br J Dermatol 1996: 134: 904-909.
6. Merk H F, Baron J M, Heise R et al. Concepts in dermatotoxicology. Exp Dermatol 2006: 15: 692-704.
7. Reeve V E, Boehm-Wilcox C, Bosnic M, Rozinova E. Suppressive effect of 2-acetyl-4-tetrahydroxybutylimidazole on contact hypersensitivity in the Skh;HR hairless mouse. Int Arch Allergy Immunol 1993: 120: 101-106.
8. Lauerma A I, Aioi A, Maibach H I. Topical cis-urocanic acid suppresses both induction and elicitation of contact hypersensitivity in BALB/c mice. Acta Derm Venereol (Stockh) 1995: 75: 272-275.
9. Harriott-Smith T G, Halliday W J. Suppression of contact hypersensitivity by short-term UV irradiation: II. the role of UCA. Clin Exp Immunol 1988: 72: 174-177.
10. Kammeyer A, Garssen J, Sleijffers A et al. Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products. Photochem Photobiol 2004: 80: 72-77.
11. Cooper K D. Atopic dermatitis: Recent trends in pathogenesis and therapy. J Invest Dermatol 1994: 102: 128-137.
12. Bialas M C, Routledge P A. Adverse effects of corticosteroids. Adverse Drug React Toxicol Rev 1998: 17: 227-235.
13. Furue M, Terao H, Rikihisa W et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003: 148: 128-133.
14. Kammeyer A, Eggelte T A, Overmars H, Bootsma A, Bos J D, Teunissen M B M. Oxidative breakdown and conversion of urocanic acid isomers by hydroxyl radical generating systems. Biochim Biophys Acta 2001: 1526: 277-285.
15. Tamura T, Matsubara M, Hasegawa K, Ohmori K, Karasawa A. Olopatidine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity. Clin Exp Allergy 2005: 35: 97-103.
16. Inoue Y, Isobe M, Shiohara T, Goto Y, Hayashi H. Protective and curative effects of topically applied CX-659S, a novel diaminouracil derivative, on chronic picryl chloride-induced contact hypersensitivity responses. Br J Dermatol 2002: 147: 675-682.
17. Inoue Y, Isobe M, Shiohara T, Hayashi H. Inhibitory activity of CX-659S, a novel diaminouracil derivative, against the rebound phenomenon following withdrawal of corticosteroid therapy for chronic contact hypersensitivity responses. Int Arch Allergy Immunol 2003: 131: 143-152.
18. Bavandi A, Fahrngruber H, Aschauer H, Hartmann B, Meingassner J G, Kalthoff F S. Pimecrolimus and tacrolimus differ in their inhibition of lymphocyte activation during the sensitization phase of contact hypersensitivity. J Dermatol Sci 2006: 43: 117-126.
19. Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Bürger A. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005: 115: 1276-1283.
20. Tamura T, Amano T, Ohmori K, Manabe H. The effects of olopatidine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice. Eur J Pharmacol 2005: 524: 149-154.
21. Mimura T, Shinozaki Y, Kawasaki H, Iwamura H. JTP-27536 [(+)-1,3- dihydroxy-2-hydroxymethylpropyl-2-ammonium 2[(R)-3-cyclohexyl- 1phenylpropyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylate monohydratel], a novel inhibitor of immunoglobulins and interleukin-5 with anti-inflammatory properties in mouse allergic dermatitis model. J Pharmacpl Exp Ther 2005: 314: 293-301.
22. Ueda Y, Inoue T, Rahman M A, Yatsuzuka R, Jiang S, Kamei C. A new chronic itch model accompanied by skin lesions in hairless mice. Int Immunopharmacol 2006: 6: 1609-1615.